Education
About Us
Working with TipRanks
Follow Us
Regeneron (REGN)
NASDAQ:REGN
REGN Stock Chart & Stats
Day’s Range― - ―
52-Week Range$520.50 - $1,211.20
Previous CloseN/A
Volume208.99K
Average Volume (3M)1.32M
Market Cap
$61.99B
Enterprise Value$55.64B
Total Cash (Recent Filing)$8.35B
Total Debt (Recent Filing)$2.70B
Price to Earnings (P/E)14.6
Beta0.66
Next Earnings
Jul 31, 2025EPS Estimate
8.53Next Dividend Ex-Date
May 20, 2025Dividend Yield0.15%
Share Statistics
EPS (TTM)8.22
Shares Outstanding106,148,350
10 Day Avg. Volume1,550,991
30 Day Avg. Volume1,316,179
Financial Highlights & Ratios
PEG Ratio5.81
Price to Book (P/B)1.92
Price to Sales (P/S)0.00
P/FCF Ratio18.55
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue1.00
Enterprise Value/Gross Profit4.65
Enterprise Value/Ebitda2.91
Forecast
1Y Price Target
$804.95Price Target Upside37.60% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering21
---
Bulls Say, Bears Say
Bulls Say
Earnings GrowthCore Dupixent and Libtayo franchises have reasonable growth expectations and should continue to drive earnings performance.
Pipeline PotentialStrong pipeline optionality with programs in melanoma and COPD could add a new dimension to the story.
Regulatory And Commercial UpdatesPositive regulatory and commercial updates likely to trigger meaningful sentiment reversal.
Bears Say
Earnings MissA 4% bottom-line miss driven primarily by lower Eylea sales.
Eylea Franchise ChallengesWeakness in the US Eylea franchise drove share underperformance.
Regulatory DelaysFDA delayed approval of Eylea HD pre-filled syringe due to manufacturing issues, creating uncertainty around its future availability.
---
Ownership Overview
1.94% Insiders
30.24% Mutual Funds
0.78% Other Institutional Investors
40.22% Public Companies and
Individual Investors
REGN FAQ
What was Regeneron’s price range in the past 12 months?
Regeneron lowest stock price was $520.50 and its highest was $1211.20 in the past 12 months.
What is Regeneron’s market cap?
Regeneron’s market cap is $61.99B.
When is Regeneron’s upcoming earnings report date?
Regeneron’s upcoming earnings report date is Jul 31, 2025 which is in 76 days.
How were Regeneron’s earnings last quarter?
Regeneron released its earnings results on Apr 29, 2025. The company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.622 by -$0.402.
Is Regeneron overvalued?
According to Wall Street analysts Regeneron’s price is currently Undervalued.
Does Regeneron pay dividends?
Regeneron pays a Notavailable dividend of $0.879 which represents an annual dividend yield of 0.15%. See more information on Regeneron dividends here
What is Regeneron’s EPS estimate?
Regeneron’s EPS estimate is 8.53.
How many shares outstanding does Regeneron have?
Regeneron has 106,148,350 shares outstanding.
What happened to Regeneron’s price movement after its last earnings report?
Regeneron reported an EPS of $8.22 in its last earnings report, missing expectations of $8.622. Following the earnings report the stock price went down -6.867%.
Which hedge fund is a major shareholder of Regeneron?
Currently, no hedge funds are holding shares in REGN
---
Regeneron Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$804.95 (37.60% Upside)
$804.95 (37.60% Upside)
Blogger Sentiment
Bullish
REGN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 28.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.5%
Last 30 Days ▼ 2.7%
Last 30 Days ▼ 2.7%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-41.89%
12-Months-Change
Fundamentals
Return on Equity
15.96%
Trailing 12-Months
Asset Growth
9.24%
Trailing 12-Months
Company Description
Regeneron
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma;Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.
---
REGN Company Deck
---
REGN Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call presented a mixed picture with strong growth in key products like Dupixent and promising pipeline advancements. However, significant challenges were highlighted, including a decline in EYLEA sales, regulatory delays for EYLEA HD, and issues with patient assistance funding. Financial stability remains strong, but the balance of highlights and lowlights points to ongoing challenges that need to be addressed.Read More>---
REGN Revenue Breakdown
44.87% EYLEA - U.S.
28.97% Sanofi
11.34% Bayer
4.11% Libtayo - U.S.
10.72% Other
---
REGN Stock 12 Month Forecast
Average Price Target
$804.95
▲(37.60% Upside)
Technical Analysis
---